DiaMedica to Present at the 2014 GTC Diabetes Summit
April 15 2014 - 9:00AM
Marketwired
DiaMedica to Present at the 2014 GTC Diabetes Summit
MINNEAPOLIS, MINNESOTA--(Marketwired - Apr 15, 2014) - DiaMedica
Inc. (TSX-VENTURE:DMA), a clinical stage biopharmaceutical company
focused on the treatment of diabetes and its complications, today
announced it will be presenting an overview of preclinical and
Phase 1 clinical results for its lead product DM199, at the 2014
GTC Diabetes Summit taking place from April 23-25, 2014, in
Cambridge, Massachusetts, USA. DiaMedica's Vice President, Clinical
and Regulatory Affairs, Dr. Mark Robbins, will be presenting the
data during the Diabetes Drug Discovery & Development
session and chairing the session on Clinical Drug Development
in Diabetes.
Presentation Details:
Title - "DM199: A Novel Form of Recombinant Human Tissue
Kallikrein-1 for the Treatment of Diabetes Mellitus"
Time - 1:30pm EDT, April 24th, 2014
Location - Hyatt Regency in Cambridge, MA
About DiaMedica
DiaMedica Inc. is a publicly traded (TSX-VENTURE:DMA) clinical
stage biopharmaceutical company focused on the discovery and
development of novel therapies to treat diabetes and the
complications associated with diabetes. DiaMedica's lead clinical
stage compound, DM199, is a recombinant human protein known as
rhKLK1 that represents a novel approach to treating diabetes and
associated complications. DiaMedica is also developing a novel
monoclonal antibody, DM204 for the treatment of Type 2 diabetes,
which is in preclinical development.
The Company is listed on the TSX Venture Exchange in Canada
under the trading symbol 'DMA'.
FORWARD-LOOKING STATEMENTS
The statements made in this press release that are not
historical facts contain forward-looking information that involves
risk and uncertainties. All statements, other than statements of
historical facts, which address DiaMedica's expectations, should be
considered forward-looking statements. Such statements are based on
management's exercise of business judgment as well as assumptions
made by and information currently available to management. When
used in this document, the words "may", "will", "anticipate",
"believe", "estimate", "expect", "intend" and words of similar
import, are intended to identify any forward-looking statements.
You should not place undue reliance on these forward-looking
statements. These statements reflect a current view of future
events and are subject to certain risks and uncertainties as
contained in the Corporation's filings with Canadian securities
regulatory authorities. Should one or more of these risks or
uncertainties materialize, or should underlying assumptions prove
incorrect, actual results could differ materially from those
anticipated in these forward-looking statements. The Corporation
undertakes no obligation, and does not intend, to update, revise or
otherwise publicly release any revisions to these forward-looking
statements to reflect events or circumstances after the date
hereof, or to reflect the occurrence of any unanticipated events.
Although management believes that expectations are based on
reasonable assumptions, no assurance can be given that these
expectations will materialize.
DiaMedica Inc.John SavageChief Financial
Officer763-208-6434info@diamedica.com
DiaMedica Inc. (TSXV:DMA)
Historical Stock Chart
From May 2024 to Jun 2024
DiaMedica Inc. (TSXV:DMA)
Historical Stock Chart
From Jun 2023 to Jun 2024